Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Subscription Offers
  • Contact
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Subscription Offers
  • Contact
Pipeline News and Updates
Picture

Update for July 13, 2021

7/13/2021

 
Regulatory Update
 
The FDA approved finerenone (Kerendia, Bayer), on 7/9/2021, to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes. Bayer set WAC for finerenone at $570 per month.
 
The FDA accepted the BLA for AstraZenec’s and Amgen’s tezepelumab for the treatment of asthma.
 
The FDA accepted the NDA for Levo Therapeutics’ intranasal carbetocin for the treatment of hyperphagia and behavioral distress associated with Prader-Willi syndrome.
 
The FDA granted Fast Track status to Opthea’s OPT-302, in combination with anti-VEGF-A therapy, for the treatment of age-related macular degeneration.
 
Announced Research Updates
 
Abeona announced six-year results from a Phase I/IIa trial, where treatment with EB-101 resulted in wound healing of 50% or more in 69% (18/26) at 3-years, 93% (14/15) at 4 years, 80% (12/15) at 5 years, and 80% (4/5) at 6 years in patients with recessive dystrophic epidermolysis bullosa.
 
Sierra announced that in the 24-week, 432 patient, Phase III, SIMPLIFY-1 trial, transfusion independence was achieved by 67% of momelotinib patients compared to 49% with ruxolitinib. Sierra announced that in the 24-week, 156 patient, open-label, Phase III, SIMPLIFY-2 trial, transfusion independence was achieved by 43% of momelotinib patients compared to 21% of patients who received best available therapy (88% ruxolitinib) in thrombocytopenic patients with primary myelofibrosis, post-polycythemia vera or post-essential thrombocythemia myelofibrosis.
 
Published Research Updates
 
In a 7-month, 1,452 patient, open-label, Phase III, trial, 11.7% of patients treated with cytisinicline achieved carbon monoxide breath test confirmed abstinence compared to 13.3% in the varenicline group in Australian adult daily smokers. The results did not reach the non-inferiority margin of a 5% difference.
 
In the 12-week, 80 patient, Phase IIa, dose ranging, BALANCED trial, treatment with efruxifermin reduced hepatic fat fraction by 12.3% with 28 mg, 13.4% with 50 mg and 14.1% with 70 mg compared to a 0.3% decrease with placebo in patients with nonalcoholic steatohepatitis (NASH).
 
In the ANGEL-MS trial, a 48 week, 154 patient, extension of the CHANGE-MS trial, treatment with temelimab did not reduce gadolinium-enhanced T1-lesions compared to placebo at week 48 or 96.
 
In the 28-week, 116 patient, Phase III CASCADE trial, treatment with tezepelumab resulted in a nominal reduction in airway submucosal inflammatory cells in bronchoscopic biopsy samples compared to placebo (ratio of geometric least-squares means 0·15) in patients with uncontrolled, moderate-to-severe asthma.
 
Roche announced that in the 1,101 patient, Phase II, IPATential150 trial, ipatasertib, added to abiraterone and prednisolone, improved radiographic progression-free survival compared to abiraterone plus prednisolone alone (18.5 months vs 16.5 months) in 521 patients with metastatic castration-resistant prostate cancer (mCRPC) with PTEN loss. In the intent-to-treat population, there was no significant improvement with the addition of ipatasertib.

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.